EMA accepts MAA for for roxadustat for the treatment of anemia in adult patients with chronic kidney disease.- Astellas + Fibrogen Inc.
Astellas Pharma Inc. and FibroGen, Inc. announced the marketing authorization application (MAA) for roxadustat for the treatment of anemia in adult patients with chronic kidney disease (CKD) has… read more.